Clinical Trial Update: Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating pharmacokinetics, safety, and tolerability of subcutaneous GAMUNEX-C in pediatric patients with primary immunodeficienc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Gamunex-C (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Primary Immunodeficiency | Phase 4 | Status: COMPLETED | Results posted: 2015-01-28